Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Recursion, Roche and Genentech unveiled the latest product of their nearly four-year artificial intelligence drug discovery collaboration. GSK ’s Blenrep was approved by the FDA for treatment of ...

The live event in Nashville, Tenn., featured 60-plus leaders, and also honored several companies with awards for supply chain excellence.

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Cipla declined 2.05% to Rs 1,508.90, extending losses for the second straight session after the company announced a management reshuffle involving the replacement of its managing director and global ...

For the Magnificent 7 group, Q3 earnings are expected to be up 11.5% from the same period last year on 15.4% higher revenues, ...

Eli Lilly And Company ( ($LLY) ) has released its Q3 earnings. Here is a breakdown of the information Eli Lilly And Company presented to its ...

As of 10 AM Eastern Time, the S&P 500 slipped 0.2%, the Dow Jones Industrial Average was up 0.5%, and the Nasdaq Composite ...

Eli Lilly and Co (LLY) reports a 54% revenue increase and raises guidance amid strong product performance and strategic ...